Moors & Cabot’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27.4M | Sell |
22,840
-410
| -2% | -$419K | 1.07% | 12 |
|
|
2026
Q1 | $21.4M | Sell |
23,250
-53
| -0.2% | -$53.7K | 0.92% | 15 |
|
|
2025
Q4 | $25M | Buy |
23,303
+1,008
| +5% | +$964K | 1.07% | 11 |
|
|
2025
Q3 | $17M | Buy |
22,295
+284
| +1% | +$211K | 0.74% | 24 |
|
|
2025
Q2 | $17.2M | Sell |
22,011
-25
| -0.1% | -$19.4K | 0.8% | 18 |
|
|
2025
Q1 | $18.2M | Buy |
22,036
+1,598
| +8% | +$1.33M | 0.92% | 18 |
|
|
2024
Q4 | $15.8M | Sell |
20,438
-983
| -5% | -$814K | 0.75% | 22 |
|
|
2024
Q3 | $19M | Buy |
21,421
+539
| +3% | +$485K | 0.94% | 15 |
|
|
2024
Q2 | $18.9M | Buy |
20,882
+1,229
| +6% | +$983K | 1.01% | 13 |
|
|
2024
Q1 | $15.3M | Sell |
19,653
-666
| -3% | -$474K | 0.83% | 23 |
|
|
2023
Q4 | $11.8M | Sell |
20,319
-85
| -0.4% | -$49.6K | 0.74% | 21 |
|
|
2023
Q3 | $11M | Sell |
20,404
-1,471
| -7% | -$758K | 0.74% | 22 |
|
|
2023
Q2 | $10.3M | Sell |
21,875
-240
| -1% | -$101K | 0.68% | 24 |
|
|
2023
Q1 | $7.59M | Buy |
22,115
+4,541
| +26% | +$1.53M | 0.52% | 34 |
|
|
2022
Q4 | $6.43M | Sell |
17,574
-3,901
| -18% | -$1.38M | 0.45% | 46 |
|
|
2022
Q3 | $6.94M | Sell |
21,475
-1,626
| -7% | -$515K | 0.53% | 39 |
|
|
2022
Q2 | $7.49M | Buy |
23,101
+169
| +0.7% | +$50.7K | 0.54% | 37 |
|
|
2022
Q1 | $6.57M | Sell |
22,932
-923
| -4% | -$238K | 0.4% | 54 |
|
|
2021
Q4 | $6.59M | Buy |
23,855
+3,306
| +16% | +$838K | 0.41% | 55 |
|
|
2021
Q3 | $4.75M | Buy |
20,549
+2,336
| +13% | +$577K | 0.3% | 74 |
|
|
2021
Q2 | $4.18M | Sell |
18,213
-173
| -0.9% | -$34.8K | 0.29% | 78 |
|
|
2021
Q1 | $3.43M | Buy |
18,386
+455
| +3% | +$89K | 0.26% | 87 |
|
|
2020
Q4 | $3.03M | Buy |
17,931
+2,640
| +17% | +$394K | 0.25% | 91 |
|
|
2020
Q3 | $2.26M | Sell |
15,291
-1,153
| -7% | -$178K | 0.21% | 105 |
|
|
2020
Q2 | $2.7M | Sell |
16,444
-1,989
| -11% | -$305K | 0.29% | 83 |
|
|
2020
Q1 | $2.56M | Sell |
18,433
-19
| -0.1% | -$2.61K | 0.37% | 68 |
|
|
2019
Q4 | $2.42M | Sell |
18,452
-787
| -4% | -$91.2K | 0.24% | 106 |
|
|
2019
Q3 | $2.15M | Buy |
19,239
+1,054
| +6% | +$117K | 0.24% | 110 |
|
|
2019
Q2 | $2.01M | Buy |
18,185
+1,828
| +11% | +$215K | 0.26% | 101 |
|
|
2019
Q1 | $2.13M | Sell |
16,357
-149
| -0.9% | -$18.1K | 0.29% | 96 |
|
|
2018
Q4 | $1.91M | Sell |
16,506
-13,460
| -45% | -$1.5M | 0.3% | 88 |
|
|
2018
Q3 | $3.21M | Sell |
29,966
-763
| -2% | -$76.3K | 0.39% | 64 |
|
|
2018
Q2 | $2.63M | Buy |
30,729
+163
| +0.5% | +$13.4K | 0.35% | 73 |
|
|
2018
Q1 | $2.37M | Buy |
30,566
+573
| +2% | +$46.1K | 0.31% | 85 |
|
|
2017
Q4 | $2.53M | Sell |
29,993
-673
| -2% | -$57.3K | 0.34% | 84 |
|
|
2017
Q3 | $2.62M | Buy |
30,666
+420
| +1% | +$34.4K | 0.38% | 68 |
|
|
2017
Q2 | $2.48M | Sell |
30,246
-1,463
| -5% | -$119K | 0.41% | 64 |
|
|
2017
Q1 | $2.67M | Sell |
31,709
-22,164
| -41% | -$1.78M | 0.45% | 55 |
|
|
2016
Q4 | $3.96M | Buy |
53,873
+27,884
| +107% | +$2.08M | 0.65% | 31 |
|
|
2016
Q3 | $2.08M | Buy |
25,989
+3,593
| +16% | +$288K | 0.35% | 74 |
|
|
2016
Q2 | $1.78M | Buy |
22,396
+1,791
| +9% | +$135K | 0.31% | 79 |
|
|
2016
Q1 | $1.48M | Sell |
20,605
-1,816
| -8% | -$137K | 0.27% | 100 |
|
|
2015
Q4 | $1.89M | Buy |
22,421
+3,594
| +19% | +$298K | 0.35% | 74 |
|
|
2015
Q3 | $1.57M | Sell |
18,827
-2,525
| -12% | -$213K | 0.29% | 85 |
|
|
2015
Q2 | $1.78M | Sell |
21,352
-48
| -0.2% | -$3.66K | 0.29% | 88 |
|
|
2015
Q1 | $1.56M | Sell |
21,400
-1,073
| -5% | -$76.4K | 0.26% | 93 |
|
|
2014
Q4 | $1.56M | Buy |
22,473
+1,357
| +6% | +$91.6K | 0.26% | 99 |
|
|
2014
Q3 | $1.36M | Buy |
21,116
+1,374
| +7% | +$87K | 0.23% | 110 |
|
|
2014
Q2 | $1.23M | Buy |
19,742
+2,461
| +14% | +$147K | 0.21% | 120 |
|
|
2014
Q1 | $1.02M | Buy |
+17,281
| New | +$964K | 0.26% | 105 |
|
Other funds holding LLY
Moors & Cabot's LLY Position: Q2 2026 in Review
Moors & Cabot reduced its Eli Lilly (LLY) stake by 1.8% in Q2 2026, selling an estimated $419K and leaving 22,840 shares worth $27.4M. The position accounts for 1.07% of the portfolio, ranked #12.
Moors & Cabot first reported a position in LLY in Q1 2014 and has held it in 50 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Moors & Cabot held 22,840 shares of Eli Lilly worth $27.4M as of Q2 2026.
- Moors & Cabot sold 410 Eli Lilly shares in Q2 2026, an estimated $419K.
- Eli Lilly made up 1.07% of Moors & Cabot's portfolio in Q2 2026, its #12 holding.
- Moors & Cabot first reported a position in Eli Lilly in Q1 2014 and has held it in 50 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.